title: Incidence and bone biopsy findings of atypical femoral fractures.
abstract: Bisphosphonates are widely used in the treatment of osteoporosis. It has been suggested that bisphosphonate treatment may be associated with atypical femoral fractures (AFFs), severely suppressed bone turnover rate, and decreased mineralization. We studied bone properties using bone quantitative histomorphometry and Fourier transform infrared spectroscopic imaging (FTIRI) on patients with AFFs. Further, the incidence of AFFs was estimated. Patient records of Kuopio University Hospital, Finland from January 2007 to June 2009 were reviewed to identify all patients who had sustained and had been operated for AFF (n = 8). The incidence of AFFs among patients on bisphosphonates was 0.61 fractures/1,000 patients per year, compared to 0.0067/1,000 per year among untreated patients. The patients that underwent bone biopsy (n = 4) were postmenopausal women (aged 55.5-81.1 years) who had been treated with bisphosphonates for over 4 years. Histomorphometry revealed low trabecular bone volume. Bone formation and resorption parameters tended to be low. Trabecular bone single labels were detected in one patient in the region of interest. In the extended label search, trabecular bone double labels were found in two patients. Based on FTIRI results, higher phosphate-to-amide I ratio and collagen maturity were found compared to normal samples. The heterogeneity of phosphate-to-amide I ratio was low. Overall incidence of atypical femoral fractures is low. The poor fracture resistance in some patients on long-term bisphosphonate-therapy could be explained by low bone formation, and changes in bone composition, i.e., higher degree of mineralization, increased collagen maturity, and decreased heterogeneity of the degree of mineralization.
authors.affiliation: Bone and Cartilage Research Unit (BCRU), University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland, inari.tamminen@uef.fi.
authors.forename: Inari S
authors.initials: IS
authors.lastname: Tamminen
authors.forename: Tero
authors.initials: T
authors.lastname: Yli-Kyyny
authors.forename: Hanna
authors.initials: H
authors.lastname: Isaksson
authors.forename: Mikael J
authors.initials: MJ
authors.lastname: Turunen
authors.forename: Xiaoyu
authors.initials: X
authors.lastname: Tong
authors.forename: Jukka S
authors.initials: JS
authors.lastname: Jurvelin
authors.forename: Heikki
authors.initials: H
authors.lastname: Kröger
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001706:Biopsy; D050071:Bone Density Conservation Agents / Q000009:adverse effects; D001842:Bone and Bones; D004164:Diphosphonates / Q000009:adverse effects; D005260:Female; D005264:Femoral Fractures / Q000139:chemically induced* / Q000453:epidemiology*; D006801:Humans; D008875:Middle Aged
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates
references.citation: Osteoporos Int. 2005 Dec;16(12):2031-8
references.pmid: 16088360
references.citation: J Clin Endocrinol Metab. 2000 Nov;85(11):4118-24
references.pmid: 11095442
references.citation: J Bone Miner Res. 1988 Apr;3(2):133-44
references.pmid: 3213608
references.citation: J Bone Miner Res. 2001 Oct;16(10):1821-8
references.pmid: 11585346
references.citation: J Biomed Opt. 2005 May-Jun;10(3):031102
references.pmid: 16229627
references.citation: Lancet. 1996 Dec 7;348(9041):1535-41
references.pmid: 8950879
references.citation: Bone. 1999 Oct;25(4):389-95
references.pmid: 10511104
references.citation: J Bone Miner Res. 2004 Dec;19(12):2000-4
references.pmid: 15537443
references.citation: J Bone Miner Res. 2012 Apr;27(4):825-34
references.pmid: 22189833
references.citation: J Clin Endocrinol Metab. 2000 Sep;85(9):3109-15
references.pmid: 10999794
references.citation: N Engl J Med. 2008 Mar 20;358(12):1304-6
references.pmid: 18354114
references.citation: J Bone Miner Res. 2011 Sep;26(9):2226-34
references.pmid: 21509822
references.citation: J Clin Endocrinol Metab. 2005 Mar;90(3):1294-301
references.pmid: 15598694
references.citation: Bone. 2002 Mar;30(3):492-7
references.pmid: 11882463
references.citation: Biomaterials. 2007 May;28(15):2465-78
references.pmid: 17175021
references.citation: N Engl J Med. 2007 May 3;356(18):1809-22
references.pmid: 17476007
references.citation: J Bone Miner Res. 2009 Jun;24(6):1095-102
references.pmid: 19113931
references.citation: J Orthop Res. 2012 Mar;30(3):435-42
references.pmid: 21882239
references.citation: Bone. 2010 Mar;46(3):666-72
references.pmid: 19925895
references.citation: J Bone Miner Metab. 2011 Jul;29(4):458-65
references.pmid: 21116831
references.citation: J Bone Miner Res. 2008 Jan;23(1):6-16
references.pmid: 17892374
references.citation: Acta Orthop. 2009 Aug;80(4):413-5
references.pmid: 19568963
references.citation: J Bone Miner Res. 2012 Mar;27(3):672-8
references.pmid: 22072397
references.citation: N Engl J Med. 1995 Nov 30;333(22):1437-43
references.pmid: 7477143
references.citation: J Clin Endocrinol Metab. 2008 Aug;93(8):2948-52
references.pmid: 18522980
references.citation: Bone. 2011 Nov;49(5):955-64
references.pmid: 21810491
references.citation: J Bone Miner Res. 2010 Jun;25(6):1360-6
references.pmid: 20200925
references.citation: J Bone Miner Res. 1987 Dec;2(6):595-610
references.pmid: 3455637
references.citation: J Bone Miner Res. 2010 Nov;25(11):2267-94
references.pmid: 20842676
references.citation: Am J Med. 1982 Feb;72(2):193-202
references.pmid: 7058831
references.citation: Osteoporos Int. 2003 Sep;14 Suppl 5:S16-20; discussion S20-1
references.pmid: 14504701
references.citation: Osteoporos Int. 2009 May;20(5):793-800
references.pmid: 18769963
references.citation: J Bone Miner Res. 2009 Sep;24(9):1565-71
references.pmid: 19419303
references.citation: Bone. 2002 Nov;31(5):620-5
references.pmid: 12477578
references.citation: N Engl J Med. 2010 May 13;362(19):1761-71
references.pmid: 20335571